大行評級丨花旗:重申比亞迪“買入”評級 料其或成行業平均售價指標
花旗發表報吿指,比亞迪股份(1211.HK)管理層預計其2025年主要銷量推動力有三。第一是低端及高端細分市場的智能先進駕駛輔助系統(ADAS)車輛,第二是純電動車(BEV)銷量的進一步提升,第三則是高壓快速充電產品。花旗認為,比亞迪2025年關鍵競爭因素為銷量、平均售價、每輛車成本及市場份額。該行指,比亞迪在這些方面均具有競爭優勢,或使其成為設定行業平均售價的指標。故重申“買入”評級,及目標價500港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.